A
Anaeropharma Science
Working on the development of novel therapeutics to target hypoxic environment in solid cancers
About Anaeropharma Science
Established in 2004, Anaeropharma Science, Inc. is a biopharmaceutical venture that originated from the research of Tetsuya Tonoike, who would later become a director, at the Industrial Technology Center of Saga. The company was founded by Yoshihiro Kakeji, a professor at Kobe University's Graduate School of Medicine, who now serves as an advisor, alongside co-founder and current President & CEO Koichi Sugiue. The firm's core focus is on developing novel anti-cancer drugs by leveraging anaerobic bacteria of the genus *Bifidobacterium*. This unique therapeutic approach, termed In-situ Delivery and Production System (IDPS), utilizes recombinant *Bifidobacterium longum* as a vector to selectively deliver and produce therapeutic proteins directly within the hypoxic microenvironments of solid tumors. The technology addresses a significant challenge in oncology: effectively targeting the oxygen-deficient core of tumors, which is often resistant to conventional therapies like chemotherapy and radiation. The genetically modified bacteria are administered intravenously and are engineered to germinate and proliferate exclusively in these hypoxic zones, transforming the tumor itself into a factory for anti-cancer agents. This targeted mechanism is designed to minimize damage to healthy tissues, a common side effect of traditional cancer treatments. Anaeropharma Science's lead pipeline candidate, APS001F, is a recombinant *Bifidobacterium longum* that expresses a cytosine deaminase, an enzyme that converts a separately administered prodrug (5-FC) into the potent anti-cancer drug 5-FU directly at the tumor site. The company is also exploring other therapeutic proteins, such as immunomodulatory agents, to be delivered via its platform. The business model centers on research and development, with the goal of partnering with larger pharmaceutical companies for late-stage clinical trials, manufacturing, and commercialization. This strategy is supported by a series of strategic funding rounds and collaborations, including a significant joint development agreement with Chugai Pharmaceutical Co., Ltd. announced in 2024.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
Growth signals
Latest recorded traffic for Anaeropharma Science is 70 monthly website visits, down 41.7% over the last three months. Anaeropharma Science's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Anaeropharma Science in the Tokyo ecosystem
The Anaeropharma Science office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Watervein Partners
Series A1 investor entered at this stage
INCJ
Series B and later4 investors entered at this stage
Seventure Partners
Shinsei Corporate Investment
Mitsubishi UFJ Capital
Syngenta
Other known investors1 additional known investor
Mitsui Global Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Anaeropharma Science on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Anaeropharma Science’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









